Clinical trial
Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma
NCT00287222 · University of Arkansas, Other · Completed
Key facts
| NCT number | NCT00287222 |
|---|---|
| Title | Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma |
| Official title | Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma |
| Lead sponsor | University of Arkansas, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatocellular Carcinoma |
| Intervention type | Drug |
| Interventions | Bevacizumab, Erlotinib |
| Enrollment | 21 |
| Start date | Feb 1, 2006 |
| Primary completion | Sep 1, 2010 |
| Completion | Sep 1, 2010 |
| First posted | Feb 6, 2006 |
| Last update posted | Jul 15, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: